Abstract: Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.

Abstract: The present application relates to methods of preparing a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof.

Abstract: A method and system optimize a thermoacoustic transducer functionality that is utilized in a thermoacoustic imaging system. The method and system select a pre-determined transducer geometry for the thermoacoustic imaging system, utilize the thermoacoustic imaging system with the pre-determined transducer geometry to generate at least one impulse in a field of view, acquire data from the impulse, reconstructing the data to generate N-dimensional impulse responses based upon respective channel responses, respective view responses, and a function of the acquired data, utilize the N-dimensional transforms for each image to generate a value for the pre-determined transducer functionality, and utilize the value for the pre-determined transducer functionality to determine an optimum thermoacoustic transducer functionality.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: Orally administrable pharmaceutical compositions and methods of administration are provided. The pharmaceutical compositions provide abuse deterrent properties.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: A system utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system uses a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive multi-polar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received multi-polar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the multi-polar acoustic signals and a distance between the boundary locations.

Abstract: The invention provides microfluidic devices, systems, and methods for manipulating an object within a channel of a microfluidic device using an external electrode. The device has a channel disposed within the device, the channel having no included electrodes. The channel has a wall, at least a portion of which is penetrable by an electric field generated external to the device, the wall being penetrable such that the electric field extends through the wall portion and into a region within the channel. The system includes the microfluidic device and an electrode external to and not bonded to the device. In the method, the external electrode is placed adjacent to the device and energized to generate an electric field that extends through the wall of the device and into the channel, thereby manipulating an object within the channel.

Abstract: Provided is a compound having the structure: (SIG)-(SI-MOD)m where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: A radio frequency applicator comprises an open-ended, hollow waveguide having an aperture therein. A solid insert is positioned within the waveguide. The solid insert has a recess formed therein that is aligned with the aperture. Filler material is provided between facing surfaces of the waveguide and the insert to fill gaps therebetween. A radio frequency (RF) source extends through the aperture and into the recess and is configured to generate RF energy pulses.

Abstract: A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.

Abstract: A method and system for estimating fractional fat content of an object of interest. The method and system include a thermoacoustic imaging system comprising an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the region of interest and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors. The one or more processors are able to process bipolar acoustic signals received by the acoustic receiver in response to RF energy pulses emitted into the region of interest using the RF applicator to determine a setting for the RF applicator that yields bipolar acoustic signals with at least one enhanced metric thereof, determine an impedance of the RF applicator used to yield acoustic bipolar signals with the enhanced at least one metric, and estimate fractional fat content of the object of interest using the determined impedance.

Abstract: A method and system for reconstructing a thermoacoustic image that utilizes the steps of directing radio frequency (RF) energy pulses generated by an RF source into a tissue region of interest; detecting, at each of a plurality of views along a scanning trajectory of a transducer element array about the region of interest, acoustic signals generated within the region of interest in response to the RF energy pulses and generating thermoacoustic data; applying at least one correction kernel to the thermoacoustic data; and after the at least one correction kernel has been applied to the thermoacoustic data, reconstructing a thermoacoustic image therefrom.

Abstract: A radio frequency applicator comprises an open-ended, hollow waveguide having an aperture therein. A solid insert is positioned within the waveguide. The solid insert has a recess formed therein that is aligned with the aperture. Filler material is provided between facing surfaces of the waveguide and the insert to fill gaps therebetween. A radio frequency (RF) source extends through the aperture and into the recess and is configured to generate RF energy pulses.

Abstract: The application relates to 4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.

Abstract: A method for diagnosing lung cancer in a subject by using a complex biomarker group is provided. The method includes steps of: (a) a computing system (1) acquiring a model M by using expression level data by individual biomarkers in the complex biomarker group and then (2) acquiring expression level data by the individual biomarkers measured from a biological specimen of the subject or their processed data Bk; and (b) the computing system determining whether lung cancer is detected in the subject by using the acquired data of the subject by referring to the model M; wherein the complex biomarker group includes CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES.